These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24011228)

  • 1. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience.
    Ceravolo F; Mascaro I; Sestito S; Pascale E; Lauricella A; Dizione E; Concolino D
    Ital J Pediatr; 2013 Sep; 39():53. PubMed ID: 24011228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan.
    Ueda K; Hokugo J
    Expert Opin Drug Saf; 2020 Jul; 19(7):891-901. PubMed ID: 32342708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.
    Tomanin R; Zanetti A; D'Avanzo F; Rampazzo A; Gasparotto N; Parini R; Pascarella A; Concolino D; Procopio E; Fiumara A; Borgo A; Frigo AC; Scarpa M
    Orphanet J Rare Dis; 2014 Sep; 9():129. PubMed ID: 25231261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
    Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
    Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
    Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
    Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
    Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
    Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
    Kim S; Whitley CB; Jarnes Utz JR
    Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
    Beck M
    Curr Pharm Biotechnol; 2011 Jun; 12(6):861-6. PubMed ID: 21235446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Giugliani R; Harmatz P; Martin R; Ramaswami U; Vellodi A; Wraith JE; Cleary M; Gucsavas-Calikoglu M; Puga AC; Shinawi M; Ulbrich B; Vijayaraghavan S; Wendt S; Conway AM; Rossi A; Whiteman DA; Kimura A
    Genet Med; 2011 Feb; 13(2):95-101. PubMed ID: 21150784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS).
    Spataro F; Viggiani F; Macchia DG; Rollo V; Tummolo A; Suppressa P; Sabba' C; Rossi MP; Giliberti L; Satriano F; Nettis E; Di Bona D; Caiaffa MF; Fischetto R; Macchia L
    Orphanet J Rare Dis; 2022 Nov; 17(1):402. PubMed ID: 36329518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.